BIAF vs. ISPC, ADXS, NVOS, HSTO, AHPI, KRBP, NBY, ENSC, KPRX, and THMO
Should you be buying bioAffinity Technologies stock or one of its competitors? The main competitors of bioAffinity Technologies include iSpecimen (ISPC), Advaxis (ADXS), Novo Integrated Sciences (NVOS), Histogen (HSTO), Allied Healthcare Products (AHPI), Kiromic BioPharma (KRBP), NovaBay Pharmaceuticals (NBY), Ensysce Biosciences (ENSC), Kiora Pharmaceuticals (KPRX), and ThermoGenesis (THMO). These companies are all part of the "medical" sector.
bioAffinity Technologies vs.
iSpecimen (NASDAQ:ISPC) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.
iSpecimen received 3 more outperform votes than bioAffinity Technologies when rated by MarketBeat users.
iSpecimen currently has a consensus price target of $7.63, indicating a potential upside of 367.79%. Given iSpecimen's higher probable upside, equities analysts clearly believe iSpecimen is more favorable than bioAffinity Technologies.
bioAffinity Technologies has lower revenue, but higher earnings than iSpecimen.
bioAffinity Technologies has a net margin of 0.00% compared to iSpecimen's net margin of -101.49%. bioAffinity Technologies' return on equity of 0.00% beat iSpecimen's return on equity.
11.6% of iSpecimen shares are owned by institutional investors. Comparatively, 2.4% of bioAffinity Technologies shares are owned by institutional investors. 32.3% of iSpecimen shares are owned by company insiders. Comparatively, 51.0% of bioAffinity Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, iSpecimen and iSpecimen both had 4 articles in the media. iSpecimen's average media sentiment score of 0.46 beat bioAffinity Technologies' score of 0.13 indicating that iSpecimen is being referred to more favorably in the media.
Summary
iSpecimen beats bioAffinity Technologies on 6 of the 11 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BIAF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
bioAffinity Technologies Competitors List
